Venmax Drugs and Pharmaceuticals Appoints New Directors
Venmax Drugs and Pharmaceuticals Limited announced the appointment of two additional directors to its board on March 30, 2026. The decisions were made during a board meeting that commenced at 4:00 P.M. and concluded at 5:00 P.M.Mrs. Padmaja Kalyani Sadhanala has been appointed as an Additional Director, serving in a Non-Executive and Non-Independent capacity. She brings over 20 years of experience in the pharmaceutical industry, holding a Post Graduate degree in Genetics and Cell Biology. Her appointment is effective from March 30, 2026, and will continue until the conclusion of the next General/Annual General Meeting, at which point she will be eligible for reappointment. Mrs. Sadhanala is the spouse of the Managing Director. She will not receive managerial remuneration.
Mr. Revoor Ramachandra has been appointed as an Additional Director, functioning as a Non-Executive and Independent Director. He holds a B.E. in Mechanical Engineering from B.M.S. College of Engineering and an M.B.A. from Bangalore University. Mr. Ramachandra possesses over 42 years of experience across industries including defense, aerospace, and automotive components. His term is for a period of five years, starting March 30, 2026, and is subject to approval from the shareholders at the next General/Annual General Meeting. Mr. Ramachandra is not related to any other director and will not receive managerial remuneration.
| Particulars | Mrs. Padmaja Kalyani Sadhanala | Mr. Revoor Ramachandra |
|---|---|---|
| Background details and Experience | Post Graduate in Genetics and Cell Biology, 20+ years in pharmaceutical industry | B.E Mechanical, M.B.A., 42+ years in defense, aerospace, automotive components |
| Date of first appointment | March 30, 2026, until next EGM/AGM | March 30, 2026, for 5 years |
| Managerial Remuneration | Nil | Nil |
| Inter-se relationship with Directors | Spouse of the Managing Director | Not related to any director |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.